Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

NCT05268016 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: ME3183
DRUG: Placebo

Sponsor

Meiji Pharma USA Inc.